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In Taiwan, type 2 diabetes mellitus (T2DM) is increasing and accounts for a high proportion of medical costs. Recent 
genome-wide scans have mapped three diabetes susceptibility loci on chromosomes 10q25.3 and 3q27, where the tran-
scription factor 7-like 2 gene (TCF7L2) and adiponectin gene (APM1) are located, respectively. This study aimed to 
explore the TCF7L2 and adiponectin gene polymorphisms in Taiwanese T2DM patients. In order to determine whether 
genetic polymorphisms of TCF7L2 and adiponectin are associated with T2DM, PCR-restriction fragment length polymor-
phism and PCR product sequencing experiments were performed to identify genetic polymorphisms in TCF7L2 rs12255372, 
rs7903146, and adiponectin single-nucleotide polymorphism (SNP)-45/SNP-276. We collected blood from unrelated 
T2DM patients and unrelated healthy controls. Our data suggest that TCF7L2 polymorphisms are rare in Taiwanese T2DM 
patients. Regarding the adiponectin gene SNP-45, T2DM patients with genotype TT had lower high-density lipoprotein-
cholesterol levels than those with genotypes TG and GG (p = 0.011). Females with genotype GG had lower levels than 
males with genotype GG (p = 0.035). Our data show that cholesterol level might be correlated with the adiponectin SNP 
gene for T2DM. The adiponectin SNP might be associated with increased cardiovascular risk in T2DM patients.
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Introduction
Type 2 diabetes mellitus (T2DM) is a heterogeneous 
disease characterized by insulin resistance and im-
paired insulin secretion. Abdominal obesity is a major 
risk factor for insulin resistance and T2DM.1 Its in-
cidence is increasing due to crapulence, aging, ur-
banization, and an increasing prevalence of obesity 
and physical inactivity. As of 2007, it was the fourth 
leading cause of death in Taiwan. It accounts for 
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98% of all diabetes, and 10% of persons over 40 
years old have the condition. In Taiwan, there are 
around 11 million patients each year with the con-
dition (about 4% of the total population). One hun-
dred thousand patients die from T2DM in Taiwan 
annually. As the population ages, the number of 
patients is expected to increase each year. Because 
of high disease burden of T2DM—including insulin 
and other treatments—it accounts for up to 11.5% 
of healthcare costs in Taiwan. In this study, we inves-
tigated the relationship between the transcription 
factor 7-like 2 protein gene (TCF7L2), adiponectin 
gene polymorphisms, and T2DM in Taiwan. We iden-
tified genetic polymorphisms in the blood of TCF7L2 
rs12255372, rs7903146, and adiponectin single-
nucleotide polymorphisms (SNP)-45/276 in unre-
lated T2DM patients and unrelated healthy control 
subjects (without diabetes).
Recent genome-wide scanning studies have 
mapped three diabetes susceptibility loci on chro-
mosome 10q25.3 and 3q27, where the TCF7L2 and 
adiponectin genes (APM1) are located, respectively. 
Common non-coding variants of the TCF7L2 gene 
were strongly associated with increased risk of T2DM 
in samples from Iceland, Denmark, and the USA.2
TCF7L2 has been implicated as a probable mem-
ber of the Wnt signaling pathway and was previ-
ously well studied in colon cancer. However, based 
on its role in intestinal cells,3 Grant et al4 proposed 
that TCF7L2 plays an important role in glucose 
metabolism by regulating the production level of 
glucagon-like peptide-1, a hormone which modifies 
glucose-dependent insulin secretion. TCF7L2 regu-
lates gene involved in cell proliferation and differ-
entiation.5 Genetic polymorphisms of the TCF7L2 
gene are one of the few validated genetic variants, 
with large effects on the risk of T2DM in popula-
tions of European ancestry.6−8
Adipose tissue, in addition to its function as 
the major energy reservoir, produces and secretes 
proteins such as adipsin9 (Figure 1), tumor necrosis 
factor-α,10 and leptin.11 APM1 (also known as GBP28) 
encodes adiponectin, which is abundantly expressed 
in adipose tissue.12−15 Adiponectin (also known as 
APM1, Acrp30, or adipoQ) is a circulating protein 
that shares significant similarities with collagens 
VIII and X and complement protein C1q.15,16 Humans 
with obesity, insulin resistance, or T2DM have lower 
plasma levels of adiponectin than normal control 
subjects.17 Adiponectin has an important role in 
glucose metabolism and is negatively correlated 
with body fat in adults.12,17 In general, adiponectin 
expression and plasma concentrations are inversely 
associated with adipose tissue mass in humans.18,19 
A decrease in adipose tissue mass among obese sub-
jects is associated with an increase in plasma adi-
ponectin concentration.12,18 Plasma adiponectin may 
act as a protective factor between adiposity and 
obesity-associated disorders (such as insulin resis-
tance and diabetes).20−24 The aim of this study was 
to explore the TCF7L2 and adiponectin polymor-
phisms for T2DM in the Taiwanese population.
Materials and Methods
Subject characteristics
We enrolled a total of 425 T2DM patients from the 
Kaohsiung Municipal United Hospital and Kaohsiung 
JD Hospital, and 500 healthy control subjects from 
the Kaohsiung JD Hospital. The healthy control sub-
jects (who did not have any form of diabetes) had 
a mean age of 46.40 ± 9.59 years, a mean body mass 
index (BMI) of 24.24 ± 4.04 kg/m2, a mean HbA1C of 
5.45 ± 0.15%, a mean AC glucose of 89.15 ± 13.55 mg/
dL, and a mean PC glucose of 85.30 ± 9.35 mg/dL. 
T2DM patients had a mean age of 66.89 ± 12.70 years, 
a mean BMI of 25.12 ± 4.36 kg/m2, a mean HbA1C of 
8.31 ± 2.14%, a mean AC glucose of 180.80 ± 81.49 mg/
dL (> 126 mg/dL), and a mean PC glucose of 217.64 ± 
83.45 mg/dL (> 200 mg/dL).
DNA analysis
Genomic DNA, isolated from peripheral blood leu-
kocytes, was purified using Ficoll-Paque PLUS (GE 
Healthcare; Milwaukee, WI, USA); purification of 
genomic DNA was completed using PureLink™ 
Genomic DNA kits (Invitrogen, Carlsbad, CA, USA).
Genotyping of polymorphisms
Genotyping was carried out by PCR-restriction frag-
ment length polymorphism (RFLP). Genomic DNA 
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Figure 1 An illustration of adiponectin function.
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was isolated from human leukocytes and PCR was 
conducted. PCR of DNA segments containing 
TCF7L2, rs12255372, rs7903146, adiponectin SNP-
45/276 was carried out with the following primers: 
rs12255372, forward primer 5-CTT GAG GTG TAC 
TGG AAA CTA AGG C-3, and reverse primer 5-CTG 
TCT ATT TGG CAT TCA AAT GGA-3; rs7903146, for-
ward primer 5-ATT GCT ATG TCC AGT TTA CAC 
ATA-3, and reverse primer 5-CTC ATA CGG CAA 
TTA AAT TAT ATG-3; SNP-45, forward primer 5-
GCA GCT CCT AGA AGT AGA CTC TGC TG-3, and 
reverse primer 5-GGA GGT CTG TGA TGA AAG AGG 
CC-3; SNP-276 forward primer 5-AAG GCC TAG 
ACA CAG GGA GA-3, and reverse primer 5-AGA 
TGC AGC AAA GCC AAA GT-3. PCR was carried out 
in a 50 μL mixture containing: 5 μL 10X PCR buffer 
(Fermentas Inc., Glen Burnie, MD, USA), 4 μL MgCl2 
(4 mM; Fermentas Inc.), 2 μ dNTP (5 mM; TaKaRa 
Bio Inc., Shiga, Japan), 10 pmol of each primer, 0.5 μL 
Taq DNA polymerase (Fermentas Inc.), 32.5 μL 
ddH2O, and 4 μL genomic DNA.
The cycling conditions for rs12255372, rs7903146, 
SNP-45, and SNP-276 were 94°C for 2 minutes, 35 
cycles of 94°C for 15 seconds, 60°C for 30 seconds, 
and 72°C for 30 seconds. This was followed by a 
final extension at 72°C for 10 minutes and a pause 
at 4°C. The PCR products were separated on a 2% 
UltraPure™ agarose gel (Invitrogen). PCR products 
were digested with 10 U/μL restriction enzymes 
(New England Biolabs, Ipswich, MA, USA). TCF7L2 
rs12255372 (Tsp509I), rs7903146 (EcoRV), adipo-
nectin SNP-45 (Sma1), and SNP-276 (EcoR1) were 
genotyped by RFLP. The digested products were 
separated on a 3% NuSieve® 3:1 agarose gel (FMC 
BioProducts, Rockland, ME, USA).
Statistical analysis
All data are shown as mean ± standard deviation. 
Clinical characteristics were compared by inde-
pendence t tests after being adjusted. Analysis of 
variance was used to compare the genotype fre-
quency differences. All statistical analyses were 
conducted using SPSS version 10.0 (SPSS Inc., 
Chicago, IL, USA).
Results
Clinical characteristics of the subjects 
enrolled in our study
T2DM patients had a higher mean age and BMI, and 
higher HbAC, AC glucose, and PC glucose levels 
(Table 1). The control subjects had a mean age of 
46.40 ± 9.59 years, a mean BMI of 24.24 ± 4.04 kg/m2, 
a mean HbA1C of 5.45 ± 0.15%, a mean AC glucose 
of 89.15 ± 13.55 mg/dL, and a mean PC glucose of 
85.30 ± 9.35 mg/dL. T2DM patients had a mean age 
of 66.89 ± 12.70 years, a mean BMI of 25.12 ± 
4.36 kg/m2, a mean HbA1C of 8.31 ± 2.14%, a mean 
AC glucose of 180.80 ± 81.49 mg/dL, and a mean PC 
glucose of 217.64 ± 83.45 mg/dL.
Clinical characteristics according to sex 
in T2DM patients
T2DM patients’ clinical characteristics, by sex, are 
shown in Table 2. Females had a higher mean total 
cholesterol and high-density lipoprotein (HDL)-cho-
lesterol levels. Males had a mean total cholesterol of 
184.14 ± 45.63 mg/dL, and a mean HDL-cholesterol 
of 44.39 ± 14.51 mg/dL. Females had a mean total 
cholesterol of 199.22 ± 57.01 mg/dL, and a mean 
HDL-cholesterol of 48.66 ± 14.06 mg/dL.
Genotype distribution according to 
nondiabetic subjects and rs12255372 
or rs7903146 in the TCF7L2 gene
Our data shows that T2DM patients were of the 
wild-type genotype (Tables 3 and 4). Alternatively, 
Table 1 Clinical characteristics of the subjects enrolled in our study*
 Nondiabetic subjects Type 2 diabetic subjects p
n 500 425 
Age (yr) 46.40 ± 9.59 66.89 ± 12.70 < 0.001†
Sex (M/F) 250/250 215/210 0.859
BMI (kg/m2) 24.24 ± 4.04 25.12 ± 4.36 0.023‡
HbA1C (%) 5.45 ± 0.15 8.31 ± 2.14 < 0.001†
AC glucose (mg/dL) 89.15 ± 13.55 180.80 ± 81.49 < 0.001†
PC glucose (mg/dL) 85.30 ± 9.35 217.64 ± 83.45 < 0.001†
Triglycerides (mg/dL) 134.92 ± 99.27 168.99 ± 87.56 < 0.001†
Total cholesterol (mg/dL) 187.83 ± 36.61 191.72 ± 52.15 0.310
HDL-cholesterol (mg/dL) 40.30 ± 2.46 46.63 ± 14.40 0.032‡
LDL-cholesterol (mg/dL) 116.67 ± 9.63 106.28 ± 35.06 < 0.001†
*Data presented as mean ± standard deviation; †p < 0.001; ‡p < 0.05.
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Table 2 Clinical characteristics, by sex, for type 2 diabetes patients*
 Male Female p
n (%) 215 (50.6) 210 (49.4) 
Age (yr) 66.95 ± 13.80 66.83 ± 11.49 0.922
BMI (kg/m2) 24.87 ± 4.64 25.42 ± 4.00 0.857
HbA1C (%) 8.25 ± 2.20 8.37 ± 2.08 0.566
AC glucose (mg/dL) 173.97 ± 80.62 187.76 ± 81.98 0.082
PC glucose (mg/dL) 208.44 ± 80.98 232.36 ± 86.02 0.112
Triglycerides (mg/dL) 162.40 ± 83.54 175.47 ± 91.11 0.153
Total cholesterol (mg/dL) 184.14 ± 45.63 199.22 ± 57.01 0.005†
HDL-cholesterol (mg/dL) 44.39 ± 14.51 48.66 ± 14.06 0.021†
LDL-cholesterol (mg/dL) 103.88 ± 34.35 108.50 ± 35.69 0.307
*Data presented as mean ± standard deviation; †p < 0.05.
Table 3 Genotype distribution for diabetic and control subjects (rs12255372, TCF7L2 gene)*
Genotypes
 Nondiabetic subjects Type 2 diabetic subjects 
 GG GG GT + TT 
p
n (%) 200 (100) 192 (99.8) 1 (0.2) 
Age (yr) 46.40 ± 9.60 65.44 ± 12.62 55 0.977
Sex (M/F) 100/100 91/101 0/1 0.514
HbA1C (%) 5.45 ± 0.16 8.72 ± 1.97 8.3 0.846
AC glucose (mg/dL) 89.15 ± 13.60 191.02 ± 87.54 162 0.762
PC glucose (mg/dL) 85.30 ± 9.43 224.75 ± 83.46 ND ND
Triglycerides (mg/dL) 134.92 ± 99.56 156.80 ± 82.56 99 0.486
Total cholesterol (mg/dL) 187.83 ± 36.77 183.77 ± 41.35 156 0.451
HDL-cholesterol (mg/dL) 44.30 ± 2.57 45.71 ± 14.39 42 0.894
LDL-cholesterol (mg/dL) 116.67 ± 9.88 106.21 ± 33.19 95 0.678
*Data presented as mean ± standard deviation or n. ND: not determined.
our results might suggest that the TCF7L2 poly-
morphisms are not often found in Taiwanese T2DM 
patients.
T2DM patients’ clinical characteristics 
according to the SNP-45 in the 
adiponectin gene
T2DM patients with genotype TT had lower HDL-
cholesterol levels (44.37 ± 12.26 mg/dL) than those 
with genotypes TG and GG (p = 0.011; Tables 5 
and 6). Females with genotype GG had lower HDL-
cholesterol levels than males with genotype GG 
(p = 0.035; Table 7).
Genotype distribution according to all 
subjects’ SNP-276 in the adiponectin gene
These data suggest that T2DM patients are wild-
type genotypes (Table 8). Our results show that 
Adiponectin SNP-276 gene polymorphisms are rare 
for T2DM patients in the Taiwanese population.
Discussion
The Wnt signaling pathway plays a well-established 
role in embryogenesis and tumourigenesis.25 How-
ever, recent data has placed Wnt signaling in the 
context of metabolic disease. In vitro and in vivo 
data have characterized the role of Wnt signaling 
molecules in the regulation of adipocyte differen-
tiation (adipogenesis).26 Furthermore, Wnts play 
a pivotal role in regulating pancreatic beta-cell 
function and mass. Studies have found polymor-
phisms within the gene encoding TCF7L2, a Wnt-
regulated transcription factor, that indicate an 
increased risk of developing T2DM.2 Genetic poly-
morphisms of the TCF7L2 gene are strongly associ-
ated with large increases in T2DM risk in different 
populations worldwide.3 In this study, we aimed to 
confirm the effect of the TCF7L2 polymorphism 
rs7903146 and rs12255372 on diabetes risk in a 
Taiwanese population and to assess the use of this 
genetic marker in improving diabetes risk prediction 
in the general population. We aimed to investigate 
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the role of TCF7L2 and adiponectin in T2DM in the 
Taiwanese population using PCR-RFLP methods. Our 
results showed that the TCF7L2 genetic polymor-
phisms are rare in T2DM patients in the Taiwanese 
population. Variants of the TCF7L2 gene have been 
associated with T2DM, but the causal variant(s) is 
still unknown. In future research, we will study the 
TCF7L2 messenger RNA expression in paired samples 
Table 4 Genotype distribution for diabetic and control subjects (rs7903146, TCF7L2 gene)*
Genotypes
 Nondiabetic subjects Type 2 diabetic subjects 
 CC CC CT + TT 
p
n (%) 150 (100) 131 (99.8) 1 (0.2) 
Age (yr) 46.40 ± 9.61 64.88 ± 12.74 60 0.688
Sex (M/F) 75/75 64/67 1/0 0.496
HbA1C (%) 5.45 ± 0.16 8.62 ± 1.97 7.6 0.826
AC glucose (mg/dL) 89.15 ± 13.63 187.99 ± 88.29 94 0.479
PC glucose (mg/dL) 85.30 ± 9.47 227.47 ± 92.49 ND ND
Triglycerides (mg/dL) 134.92 ± 99.72 163.22 ± 86.65 78 0.291
Total cholesterol (mg/dL) 187.83 ± 36.86 184.66 ± 42.82 152 0.423
HDL-cholesterol (mg/dL) 44.30 ± 2.63 45.23 ± 13.66 45 0.948
LDL-cholesterol (mg/dL) 116.67 ± 10.04 106.97 ± 36.08 91 0.638
*Data presented as mean ± standard deviation or n. ND: not determined.
Table 5 Type 2 diabetic patients’ clinical characteristics by genotype (SNP-45 in the adiponectin gene)*
Genotypes
 SNP-45  
p
 TT TG GG 
n (%) 210 (49.4) 196 (46.1) 19 (4.5) 
Age (yr) 65.72 ± 12.41 68.20 ± 12.89 66.42 ± 13.13 0.143
Sex (M/F) 107/103 94/102 14/5 0.100
BMI (kg/m2) 25.70 ± 3.85 25.00 ± 3.70 26.40 ± 3.51 0.485
HbA1C (%) 8.28 ± 2.16 8.34 ± 2.14 8.27 ± 1.93 0.953
AC glucose (mg/dL) 177.25 ± 81.73 186.99 ± 82.61 167.32 ± 68.25 0.317
PC glucose (mg/dL) 213.34 ± 80.54 218.22 ± 83.97 206.86 ± 87.67 0.912
Triglycerides (mg/dL) 171.64 ± 85.75 165.83 ± 90.53 171.41 ± 80.81 0.820
Total cholesterol (mg/dL) 194.79 ± 59.67 189.60 ± 43.71 178.71 ± 36.97 0.368
HDL-cholesterol (mg/dL) 44.37 ± 12.26 49.01 ± 16.43 50.43 ± 14.25 0.033
LDL-cholesterol (mg/dL) 108.25 ± 36.02 104.18 ± 34.56 103.25 ± 29.85 0.653
*Data presented as mean ± standard deviation or n.
Table 6 Type 2 diabetic patients’ clinical characteristics by genotype (SNP-45 in the adiponectin gene)*
Genotypes
 SNP-45
 TT TG + GG 
p
n (%) 210 (49.4) 215 (50.6) 
Age (yr) 65.72 ± 12.41 68.04 ± 12.89 0.059
Sex (M/F) 107/103 108/107 0.882
BMI (kg/m2) 25.70 ± 3.85 25.10 ± 3.68 0.369
HbA1C (%) 8.28 ± 2.16 8.33 ± 2.11 0.777
AC glucose (mg/dL) 177.25 ± 81.73 185.25 ± 81.49 0.256
PC glucose (mg/dL) 213.34 ± 80.54 217.09 ± 83.76 0.798
Triglycerides (mg/dL) 171.64 ± 85.75 166.35 ± 89.49 0.563
Total cholesterol (mg/dL) 194.79 ± 59.67 188.62 ± 43.17 0.250
HDL-cholesterol (mg/dL) 44.37 ± 12.26 49.16 ± 16.16 0.011†
LDL-cholesterol (mg/dL) 108.25 ± 36.02 104.08 ± 33.98 0.357
*Data presented as mean ± standard deviation or n; †p < 0.05.
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Table 7 Type 2 diabetic patients’ clinical characteristics by genotype (SNP-45 in the adiponectin gene)*
Genotypes
 SNP-45
 TT + TG GG 
p
n (%) 406 (95.5) 19 (4.5) 
Age (yr) 66.90 ± 12.70 66.42 ± 13.13 0.868
Sex (M/F) 201/205 14/5 0.035†
BMI (kg/m2) 25.31 ± 3.77 26.40 ± 3.51 0.527
HbA1C (%) 8.31 ± 2.15 8.27 ± 1.93 0.947
AC glucose (mg/dL) 181.43 ± 82.08 167.32 ± 68.25 0.461
PC glucose (mg/dL) 215.88 ± 82.04 206.86 ± 87.67 0.778
Triglycerides (mg/dL) 168.87 ± 87.98 171.41 ± 80.81 0.907
Total cholesterol (mg/dL) 192.33 ± 52.71 178.71 ± 36.97 0.293
HDL-cholesterol (mg/dL) 46.43 ± 14.42 50.43 ± 14.25 0.349
LDL-cholesterol (mg/dL) 106.44 ± 35.36 103.25 ± 29.85 0.760
*Data presented as mean ± standard deviation or n; †p < 0.05.
Table 8 Genotype distribution and diabetes status for SNP-276 in the adiponectin gene*
Genotypes
 Nondiabetic subjects Type 2 diabetic subjects 
 GG GG 
p
n 200 198 
Age (yr) 46.40 ± 9.60 64.92 ± 12.80 < 0.001†
Sex (M/F) 100/100 94/104 0.615
HbA1C (%) 5.45 ± 0.16 8.71 ± 1.95 < 0.001†
AC glucose (mg/dL) 89.15 ± 13.60 191.68 ± 86.74 < 0.001†
PC glucose (mg/dL) 85.30 ± 9.43 223.75 ± 82.56 < 0.001†
Triglycerides (mg/dL) 134.92 ± 99.56 157.71 ± 82.05 0.038‡
Total cholesterol (mg/dL) 187.83 ± 36.77 183.38 ± 41.01 0.422
HDL-cholesterol (mg/dL) 44.30 ± 2.57 45.54 ± 14.39 0.395
LDL-cholesterol (mg/dL) 116.67 ± 9.88 105.94 ± 33.80 0.009‡
*Data presented as mean ± standard deviation or n; †p < 0.001; ‡p < 0.05.
of visceral and subcutaneous adipose tissue from 
paired subjects using quantitative real-time PCR 
and examine its relation to obesity and T2DM.
Several association studies exploring T2DM and 
adiponectin gene polymorphisms have been re-
ported with conflicting results.27 Our study attempted 
to identify the genetic defects of the adiponectin 
(APM1) gene that contribute to the development 
of T2DM. We also aimed to determine the func-
tional SNPs in the APM1 gene associated with T2DM 
in the Taiwanese population. Our aim was to exam-
ine the association of two polymorphisms (+45T > G 
and +276G > T) in the adiponectin gene with T2DM 
and pre-diabetic quantitative traits in the Taiwanese 
population. The study groups comprised 425 unre-
lated T2DM patients and 500 controls.
Aside from T2DM, adiponectin might be associ-
ated with increased cardiovascular risk. This study 
also aimed to investigate the relationship between 
adiponectin SNPs and cardiovascular events in pa-
tients with T2DM with an adverse cardiovascular 
risk profile. Here, we confirm a positive relationship 
between adiponectin gene SNP-45, genotype GG, 
and HDL-cholesterol levels in T2DM patients. In fu-
ture research, we will investigate the association 
between the 45T/G SNP and plasma adiponectin 
levels, and the prevalence of T2DM in the Taiwanese 
population. An enzyme-linked immunosorbent as-
say will be used to determine plasma adiponectin 
levels.
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